Artwork

Labiotech द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री Labiotech या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal
Player FM - पॉडकास्ट ऐप
Player FM ऐप के साथ ऑफ़लाइन जाएं!

New class of small molecule therapeutics introduced

26:35
 
साझा करें
 

Manage episode 385552351 series 3361449
Labiotech द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री Labiotech या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal

On this week’s podcast we have a conversation with Jordi Mata-Fink, co-founder and chief executive officer of the newly-launched U.S. company Gate Bioscience.

00:45-01:06: About Gate Bioscience
01:06-02:09: What are disease-causing extracellular proteins?
02:09-04:44: How have diseases caused by extracellular proteins been treated in the past?
04:44-05:47: Have there been diseases that haven’t been addressed?
05:47-07:05: Tackling the different issues created by extracellular proteins
07:05-09:41: What are molecular gates?
09:41-12:56: How does your technique distinguish between good and bad extracellular proteins?
12:56-16:24: How did the idea become a company?
16:24-17:24: Which diseases will you focus on?
17:24-18;47: How do you address costs?
18:47-19:11: How will this be given to patients?
19:11-20:01: Disease cure or disease management?
20:01-21:35: How was the company created?
21:35-24:18: The rise of small molecules
24:18-25:58: What are the next steps?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

अध्यायों

1. New class of small molecule therapeutics introduced (00:00:00)

2. About Gate Bioscience
 (00:00:45)

3. What are disease-causing extracellular proteins? (00:01:06)

4. How have diseases caused by extracellular proteins been treated in the past?
 (00:02:09)

5. Have there been diseases that haven’t been addressed?
 (00:04:44)

6. Tackling the different issues created by extracellular proteins
 (00:05:47)

7. What are molecular gates?
 (00:07:05)

8. How to distinguish between good and bad extracellular proteins
 (00:09:41)

9. How did the idea become a company?
 (00:12:56)

10. Which diseases will you focus on?
 (00:16:24)

11. How do you address costs? (00:17:24)

12. How will this be given to patients? (00:18:47)

13. Disease cure or disease management? (00:19:11)

14. How was Gate created?
 (00:20:01)

15. The rise of small molecules
 (00:21:35)

16. What are the next steps for Gate Bioscience?
 (00:24:18)

124 एपिसोडस

Artwork
iconसाझा करें
 
Manage episode 385552351 series 3361449
Labiotech द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री Labiotech या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal

On this week’s podcast we have a conversation with Jordi Mata-Fink, co-founder and chief executive officer of the newly-launched U.S. company Gate Bioscience.

00:45-01:06: About Gate Bioscience
01:06-02:09: What are disease-causing extracellular proteins?
02:09-04:44: How have diseases caused by extracellular proteins been treated in the past?
04:44-05:47: Have there been diseases that haven’t been addressed?
05:47-07:05: Tackling the different issues created by extracellular proteins
07:05-09:41: What are molecular gates?
09:41-12:56: How does your technique distinguish between good and bad extracellular proteins?
12:56-16:24: How did the idea become a company?
16:24-17:24: Which diseases will you focus on?
17:24-18;47: How do you address costs?
18:47-19:11: How will this be given to patients?
19:11-20:01: Disease cure or disease management?
20:01-21:35: How was the company created?
21:35-24:18: The rise of small molecules
24:18-25:58: What are the next steps?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

  continue reading

अध्यायों

1. New class of small molecule therapeutics introduced (00:00:00)

2. About Gate Bioscience
 (00:00:45)

3. What are disease-causing extracellular proteins? (00:01:06)

4. How have diseases caused by extracellular proteins been treated in the past?
 (00:02:09)

5. Have there been diseases that haven’t been addressed?
 (00:04:44)

6. Tackling the different issues created by extracellular proteins
 (00:05:47)

7. What are molecular gates?
 (00:07:05)

8. How to distinguish between good and bad extracellular proteins
 (00:09:41)

9. How did the idea become a company?
 (00:12:56)

10. Which diseases will you focus on?
 (00:16:24)

11. How do you address costs? (00:17:24)

12. How will this be given to patients? (00:18:47)

13. Disease cure or disease management? (00:19:11)

14. How was Gate created?
 (00:20:01)

15. The rise of small molecules
 (00:21:35)

16. What are the next steps for Gate Bioscience?
 (00:24:18)

124 एपिसोडस

All episodes

×
 
Loading …

प्लेयर एफएम में आपका स्वागत है!

प्लेयर एफएम वेब को स्कैन कर रहा है उच्च गुणवत्ता वाले पॉडकास्ट आप के आनंद लेंने के लिए अभी। यह सबसे अच्छा पॉडकास्ट एप्प है और यह Android, iPhone और वेब पर काम करता है। उपकरणों में सदस्यता को सिंक करने के लिए साइनअप करें।

 

त्वरित संदर्भ मार्गदर्शिका